Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Vertex Pharmaceuticals Inc banner

Vertex Pharmaceuticals Inc
F:VX1

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
F:VX1
Watchlist
Price: 455.5 EUR 3.12% Market Closed
Market Cap: €117.7B
Write Note Create Alert Ask AI

Wall St Price Targets

VX1 Price Forecast
Based on 31 analysts

+11% Upside
from €455.5 today

VX1 Analyst Rating
No ratings yet

No rating

We don't have analyst ratings for VX1 yet.

Vertex Pharmaceuticals Inc Competitors:
Price Targets

Revenue
Forecast

17% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
17% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.

What are analyst estimates?

Gross Profit
Forecast

17% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
17% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 8 years is 10%.

What are analyst estimates?

Operating Income
Forecast

42% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss
42% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.

What are analyst estimates?

Pre-Tax Income
Forecast

47% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss
47% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 47%. The projected CAGR for the next 3 years is 21%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
N/A
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

The compound annual growth rate for Net Income over the next 8 years is 14%.

What are analyst estimates?

Continue VX1 Research

Summary
VX1 intrinsic value, competitors valuation, and company profile.
DCF Valuation
VX1 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VX1 stock valuation using valuation multiples.
Wall St Estimates
VX1 price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VX1 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Vertex Pharmaceuticals Inc listings:
NASDAQ • USD
VRTX
 LSE • USD
0QZU
 XETRA • EUR
VX1
 XHAM • EUR
VX1
 BMV • MXN
VRTX
 XMUN • EUR
VX1
 SWB • EUR
VX1
 DUS • EUR
VX1
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is VX1's stock price target?
Price Target
506.04 EUR

According to Wall Street analysts, the average 1-year price target for VX1 is 506.04 EUR with a low forecast of 303.68 EUR and a high forecast of 606.16 EUR.

What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.

What is the Gross Profit forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 8 years is 10%.

What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%

Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.

What is the Pre-Tax Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
21%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 47%. The projected CAGR for the next 3 years is 21%.

What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
14%

The compound annual growth rate for Net Income over the next 8 years is 14%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.